Compare ATEC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | MNKD |
|---|---|---|
| Founded | 1990 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2006 | 2004 |
| Metric | ATEC | MNKD |
|---|---|---|
| Price | $9.21 | $4.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $22.00 | $8.69 |
| AVG Volume (30 Days) | 1.8M | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $101,739,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $18.97 | $35.81 |
| Revenue Next Year | $16.70 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $6.82 | $2.23 |
| 52 Week High | $23.29 | $6.51 |
| Indicator | ATEC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 50.66 |
| Support Level | $8.99 | $3.74 |
| Resistance Level | $9.57 | $4.23 |
| Average True Range (ATR) | 0.35 | 0.15 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 32.07 | 38.76 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.